Investments
100Portfolio Exits
26Funds
1Partners & Customers
4About Takeda Ventures
Takeda Ventures, (TVI), is the corporate venture arm of Takeda Pharmaceutical Company (TPC) a world-class pharmaceutical company and the largest in Japan. TVI now assumes the role of Takedas former venture investment group, Takeda Research Investment, and remains a wholly owned subsidiary of Takeda America Holdings.The new group continues to seek strategic opportunities to complement and extend internal discovery capabilities, but will additionally explore potentially new business avenues for Takeda through external strategic venture activities. The firm's aim is to encourage and support therapeutic innovation in the biopharmaceutical sector, as well as academic centers of excellence, through early stage capital investment and provision of access to the resources of a multinational pharmaceutical company.
Latest Takeda Ventures News
Nov 30, 2023
Harness Therapeutics , a Cambridge, UK-based biotechnology company focused on physiological protein upregulation, raised additional £4M in funding. The round brought the total amount to £17.6M. Backers included SV Health Investors, investing out of The Dementia Discovery Fund (DDF) and Takeda Ventures. The company intends to use the funds to advance its lead programme targeting FAN1 nuclease in Huntington’s Disease (HD) towards the clinic. Led by CEO Jan Thirkettle, Harness Therapeutics is a biotechnology company focused on the development of therapeutics for the treatment of neurodegenerative diseases, with a programme in Huntington’s Disease. Focusing on neurodegeneration targets with strong biology and genetic validation, it utilises its understanding of RNA biology and post-transcriptional regulation to enable drugging with oligonucleotide based drugs to upregulate protein expression. Harness Therapeutics was originally established as Transine Therapeutics in 2020 by life science investors Takeda Ventures and The Dementia Discovery Fund (DDF), with Epidarex Capital joining as an investor in 2022. the company initially focussed on advancing its IncRNA “SINEUP” platform for upregulation of protein expression and the investment committed through this period has enabled Harness to build deep RNA biology alongside bespoke analytical capabilities. From this work, the company has gained insights into the regulation of therapeutic targets and broadened its oligonucleotide based toolset for physiological protein upregulation. FinSMEs
Takeda Ventures Investments
100 Investments
Takeda Ventures has made 100 investments. Their latest investment was in Crescendo Biologics as part of their Series C on July 7, 2023.
Takeda Ventures Investments Activity
Date | Round | Company | Amount | New? | Co-Investors | Sources |
|---|---|---|---|---|---|---|
7/24/2023 | Series C | Crescendo Biologics | $32M | No | 1 | |
5/23/2023 | Series A | Larkspur Biosciences | Yes | 3 | ||
5/12/2023 | Series D | OncoResponse | $14M | Yes | 3B Future Health Fund, ARCH Venture Partners, Bering Capital, Canaan Partners, InterVest, RiverVest Venture Partners, and Undisclosed Investors | 3 |
2/13/2023 | Series B - III | |||||
1/5/2023 | Series B |
Date | 7/24/2023 | 5/23/2023 | 5/12/2023 | 2/13/2023 | 1/5/2023 |
|---|---|---|---|---|---|
Round | Series C | Series A | Series D | Series B - III | Series B |
Company | Crescendo Biologics | Larkspur Biosciences | OncoResponse | ||
Amount | $32M | $14M | |||
New? | No | Yes | Yes | ||
Co-Investors | 3B Future Health Fund, ARCH Venture Partners, Bering Capital, Canaan Partners, InterVest, RiverVest Venture Partners, and Undisclosed Investors | ||||
Sources | 1 | 3 | 3 |
Takeda Ventures Portfolio Exits
26 Portfolio Exits
Takeda Ventures has 26 portfolio exits. Their latest portfolio exit was Turnstone Biologics on July 21, 2023.
Date | Exit | Companies | Valuation Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model. | Acquirer | Sources |
|---|---|---|---|---|---|
7/21/2023 | IPO | Public | 2 | ||
6/29/2023 | Acquired | 3 | |||
11/16/2022 | Acquired | 12 | |||
Date | 7/21/2023 | 6/29/2023 | 11/16/2022 | ||
|---|---|---|---|---|---|
Exit | IPO | Acquired | Acquired | ||
Companies | |||||
Valuation | |||||
Acquirer | Public | ||||
Sources | 2 | 3 | 12 |
Takeda Ventures Fund History
1 Fund History
Takeda Ventures has 1 fund, including TRI Fund.
Closing Date | Fund | Fund Type | Status | Amount | Sources |
|---|---|---|---|---|---|
TRI Fund | UNKNOWN | Open | 1 |
Closing Date | |
|---|---|
Fund | TRI Fund |
Fund Type | UNKNOWN |
Status | Open |
Amount | |
Sources | 1 |
Takeda Ventures Partners & Customers
4 Partners and customers
Takeda Ventures has 4 strategic partners and customers. Takeda Ventures recently partnered with Crescendo Biologics on July 7, 2019.
Date | Type | Business Partner | Country | News Snippet | Sources |
|---|---|---|---|---|---|
7/23/2019 | Licensor | United Kingdom | Crescendo Biologics Second Oncologytargeted Humabody Licensed by Takeda This is the second license option that Takeda Ventures has exercised under the agreement with Crescendo Biologics and relates to the continued progression of an immuno-oncology programme . | 1 | |
3/28/2019 | Licensee | ||||
3/2/2017 | Partner | ||||
4/11/2011 | Partner |
Date | 7/23/2019 | 3/28/2019 | 3/2/2017 | 4/11/2011 |
|---|---|---|---|---|
Type | Licensor | Licensee | Partner | Partner |
Business Partner | ||||
Country | United Kingdom | |||
News Snippet | Crescendo Biologics Second Oncologytargeted Humabody Licensed by Takeda This is the second license option that Takeda Ventures has exercised under the agreement with Crescendo Biologics and relates to the continued progression of an immuno-oncology programme . | |||
Sources | 1 |
Takeda Ventures Team
8 Team Members
Takeda Ventures has 8 team members, including current Chief Executive Officer, President, Graeme R. Matin.
Name | Work History | Title | Status |
|---|---|---|---|
Graeme R. Matin | Chief Executive Officer, President | Current | |
Name | Graeme R. Matin | ||||
|---|---|---|---|---|---|
Work History | |||||
Title | Chief Executive Officer, President | ||||
Status | Current |
Loading...